A Study to Explore Safety, Pharmacokinetics, and Early Clinical Signal of Efficacy of DS-2325a in Patients With Netherton Syndrome

Summary

Netherton Syndrome (NS) is a severe rare disease characterized by generalized scaling, erythema, and epidermal barrier defects. This study assessed the safety, pharmacokinetics (PK), and efficacy of DS-2325a in patients with NS.

Timeline

Start

2023-09-28

Primary completion

2025-01-06

Completion

2025-01-06

Outcome

Outcome not reported

Stopped (Business): “The study was terminated based on a business decision by the Sponsor.”

Drugs

Indications